Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cyclin D-binding Myb-like transcription factor 1 (DMTF1) is a transcription factor with a cyclin D-binding domain and Myb-like repeats, functioning as a tumor suppressor largely via activation of the ARF–p53 pathway; it mediates growth arrest and apoptosis in response to oncogenic stress (notably Ras pathway activation), and plays important roles in cell cycle regulation, hematopoietic differentiation, and transcription of specific genes such as ARF and aminopeptidase N. DMTF1 is present in multiple isoforms, with the α isoform serving as a potent transcriptional activator and tumor suppressor, while β and γ isoforms can antagonize α function, sometimes promoting proliferation. Deletions, aberrant splicing, or downregulation of DMTF1 are implicated in the pathogenesis of several cancer types.
Not directly targeted by approved drugs (as of current knowledge); Potential indirect action by modulation of ARF–p53 pathway, Ras signaling, or splicing regulators
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cyclin D-binding Myb-like transcription factor 1 (DMTF1).